Peter S Roddy Net Worth

The estimated Net Worth of Peter S Roddy is at least $451 Thousand dollars as of 19 December 2014. Peter Roddy owns over 16,502 units of Vermillion stock worth over $451,448 and over the last 14 years Peter sold VRML stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Peter Roddy VRML stock SEC Form 4 insiders trading

Peter has made over 1 trades of the Vermillion stock since 2014, according to the Form 4 filled with the SEC. Most recently Peter bought 16,502 units of VRML stock worth $23,763 on 19 December 2014.

The largest trade Peter's ever made was buying 16,502 units of Vermillion stock on 19 December 2014 worth over $23,763. On average, Peter trades about 1,375 units every 0 days since 2010. As of 19 December 2014 Peter still owns at least 112,862 units of Vermillion stock.

You can see the complete history of Peter Roddy stock trades at the bottom of the page.

What's Peter Roddy's mailing address?

Peter's mailing address filed with the SEC is C/O VERMILLION, 12117 BEE CAVE RD, BLDG 3-100, AUSTIN, TX, 78738.

Insiders trading at Vermillion

Over the last 17 years, insiders at Vermillion have traded over $1,008,376 worth of Vermillion stock and bought 29,557,130 units worth $34,088,488 . The most active insiders traders include Jack W Schuler, Henri George Schuler, and Larry Noracle Partners Lp F.... On average, Vermillion executives and independent directors trade stock every 59 days with the average trade being worth of $1,572,028. The most recent stock trade was executed by Robert Harry Beechey on 15 November 2019, trading 5,000 units of VRML stock currently worth $3,550.

What does Vermillion do?

Vermillion, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.

Complete history of Peter Roddy stock trades at Cytokinetics Inc and Vermillion

Vermillion executives and stock owners

Vermillion executives and other stock owners filed with the SEC include:

• Valerie Palmieri,
  President, Chief Executive Officer, Director
• Robert Beechey,
  Chief Financial Officer
• Nancy Cocozza,
  Independent Director
• James LaFrance,
  Independent Chairman of the Board
• Veronica Jordan,
  Independent Director
• David Schreiber,
  Independent Director
• James Burns,
  Independent Director
• Sandra Brooks,
  Independent Director
• Jack W Schuler,
  
• Peter S Roddy,
  Director
• Carl Severinghaus,
  Director
• Larry Noracle Partners Lp O...,
  
• Donald G Munroe,
  SVP Business Development & CSO
• Henri George Schuler,
  10% owner
• Holly B Bauzon,
  VP Managed Markets
• Fred Ferrara,
  Chief Information Officer
• Rajen Dalal,
  Director
• Gail S Page,
  President and CEO
• Qun Zhou,
  Interim CFO
• Laura Ann Miller,
  SVP Sales & Cust Experience
• Robert St Leger Goggin,
  Director
• Ashish Kohli,
  VP of Corporate Strategy
• Michael J Callaghan,
  Director
• Marian E Sacco,
  See Remarks
• Thomas H Mclain,
  CEO & President
• James L Rathmann,
  Director
• Eric Varma,
  Director
• Larry Noracle Partners Lp O...,
  
• John F Hamilton,
  Director
• William C Wallen,
  Director
• Bruce A Huebner,
  Director
• William B. Creech,
  VP Sales and Marketing
• Eric Schoen,
  VP Finance & CAO
• Eric T Fung,
  VP-Chief Science Officer
• Sandra A. Gardiner,
  VP & Chief Financial Officer
• Judy Bruner,
  Director
• Partners L Pwiggins James P...,
  
• Diagnostics Inc Quest,
  10% owner
• Kenneth J Conway,
  Director
• Simon C. Shorter,
  VP, Corp Business Development
• John A Young,
  Director
• Larry Noracle Partners Lp F...,